key: cord-0817749-vvbhndkf
authors: Gray, Gregory C; Abdelgadir, Anfal
title: While We Endure this Pandemic What New Respiratory Virus Threats Are We Missing?
date: 2021-02-12
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab078
sha: e815f5c0fb276fc5d513477b5c0c0155bdfd2d9f
doc_id: 817749
cord_uid: vvbhndkf

In this paper we review recent human respiratory virus epidemics, their zoonotic nature, and our current inability to identify future prepandemic threats. We propose a cost-efficient, One Health surveillance strategy that will be more efficient and more sustainable than previous efforts.

M a n u s c r i p t

The COVID-19 pandemic has preoccupied healthcare and public health professionals for more than a year. We are assured that the future holds new emergent respiratory virus threats that could be equally devastating. What virus types should we anticipate? Where do we conduct surveillance for them? How do we better mitigate such prepandemic threats before they cause worldwide morbidity?

In addition to the widely recognized novel influenza A and coronavirus threats, other respiratory viruses have epidemic if not pandemic potential. These include human metapneumovirus, 1,2 human respirovirus 3 (formerly parainfluenza virus 3), 1 rhinovirus C, 3 respiratory syncytial virus, and multiple human adenovirus species. 4 Many of these threats are now recognized as zoonotic (here we equate anthroponosis or reverse zoonosis with zooanthroponosis because zoonoses are often recognized as bidirectional).

The zoonotic nature of some of these viruses was not always appreciated. Human respirovirus 3, and human rhinovirus 3 had not previously been thought to be zoonotic.

Cross-species spillovers of metapneumovirus 5 and adenoviruses 6 have been previously postulated, but until recently 1,2 were largely discounted. 7, 8 There is growing evidence that adenoviruses 9 and enteroviruses 10 are, at least occasionally, jumping species. The zoonotic nature of such pathogens matters because the viruses responsible for the 2009 H1N1 pandemic and the current COVID-19 pandemic came from animals and A c c e p t e d M a n u s c r i p t 4 have both abjectly surprised public health officials with their rapid spread and high morbidity. We argue that their emergence was not expected because sparse surveillance was being performed at the human-animal interface.

The impact of novel respiratory virus infections in humans is not trivial (Figure 1 causing an estimated 60.8 million illnesses and 12,469 deaths in the United States alone. 14 The deadly influenza strain continues to circulate today. In 1969, enterovirus A71 (EV-A71) was first isolated in California, with outbreaks from 1972-1990 identified in six countries. 11 In the Asian-Pacific region, EV-A71 became endemic in the 1990s, affecting thousands of children to manifest what is recognized as hand, foot, and mouth disease. 11 While surveillance is still sparse, the virus has caused at least 12.8M infections and 3747 deaths in Asia alone, with major outbreaks continuing to occur every 3-4 years. 11 Enterovirus D68 was first isolated in California in 1962, and since then, there have been infrequent cases in the USA and minor outbreaks in Europe, Africa, and Southeast Asia. In 2014, a novel clade of a 2 nd enterovirus D68 (EV-D68) was implicated in a series of outbreaks of respiratory disease in 21 countries. There were at least 2,287 EV-D68 illnesses and 17 deaths attributed to this virus. 16 The virus has also A c c e p t e d M a n u s c r i p t 5 caused outbreaks of severe respiratory disease in Asia and was recently implicated as the cause of acute flaccid myelitis. 18 It is unfortunate that our public health response to recent emergent novel pathogen events has largely been transient. Former CDC Director, Julie Gerberding, MD, addressed this concern in her November 2019 testimony 19 

Beyond causing high morbidity and mortality, emerging respiratory viruses have also had major impacts upon international travel, trade, and economies. In a 2018 report, 21 The World Bank estimated that the SARS epidemic cost the affected nations US$30-50 billion, and the H1N1 pandemic US$45-55 billion. An incursion of MERS-CoV in South Korea during June 2015 to June 2016 was estimated to cost that nation US$2.6 billion. 22 At this juncture, it is clear that the economic impact of COVID-19 will exceed all recent respiratory disease outbreaks.

Most of these novel emergent respiratory viruses come from four different viral families (Coronaviridae, Adenoviridae, Orthomyxoviridae, and Picornaviridae) and are thought to have originated in animals before crossing over to infect humans. Epidemiologists, ecologists, and modelers have attempted to predict novel pathogen emergence. Studies have been conducted to identify risk factors associated with emerging influenza A viruses, 23 emerging infectious diseases, 24 and emerging zoonotic diseases. 25 The identified risk factors for specific viruses are complex and sometimes disparate. However, these factors often point to densely populated geographical areas in Asia as areas of high emerging infectious disease risk. They also point to encounters with live animals, especially around markets where animals are sold, 26,27 as a source of virus mixing and human infection risk.

The time and process for viruses to transition or adapt from an animal virus to a human zoonotic pathogen are unknown, but it seems logical that it takes many years and varies with each zoonotic pathogen (Figure 2) . For instance, viral evolutionary data suggest that the coronavirus lineage giving rise to SARS-CoV-2 departed from the nearest similar virus in bats A c c e p t e d M a n u s c r i p t 7 after ~1969. 28 While the virus likely circulated in bats or in an intermediate animal host during some of this time, it seems likely that the virus took quite some time in adapting to humans and longer still to become the pathogen we face today. These long transition periods provide an important opportunity to mitigate novel respiratory virus threats before they fully adapt to humans and become highly transmissible.

If we focus novel pathogen surveillance at the human-animal nexus (Figure 2) we are likely to be more efficient in detecting pathogens that threaten humans, as compared to other more ambitious surveillance strategies which focus upon the comprehensive study of all the viruses that reside in the world's animals. In embracing the latter approach, programs such as USAID's PREDICT I and II programs and the new Global Virome Project have been criticized as expensive and not likely to find pathogens which will be human threats. Their previous costs (PREDICT >$169M since 2009), future proposed costs (Global Virome Project $3.4B), and ambitious plans have been questioned. [29] [30] [31] [32] [33] Similarly, leaders at the US National Institute of Allergy and Infectious Diseases have proposed 20 years of large human cohort studies and intensive immunology and pathology research involving 120 pathogen groups, 34 -36 yet freely admit the associated cost is prohibitive. 34 There is a growing demand for innovative and cost-effective approaches to surveil for the next novel respiratory virus threat. We need to mitigate novel respiratory virus threats before they fully adapt to humans and become highly transmissible. The most strategic approach would be directing periodic, novel respiratory virus surveillance at the human-animal interface, studying both animal workers and their animals. 37 Alternatively, if surveillance cannot be conducted at the human-animal interface, surveillance for novel respiratory viruses among human pneumonia patients should be conducted in geographical areas known to be at high risk of novel respiratory virus emergence. We have recently used these methods and found evidence for novel zoonotic coronaviruses among humans hospitalized with pneumonia, 38 a A c c e p t e d M a n u s c r i p t 8 zoonotic adenovirus infection in a patient with respiratory illness, 39 evidence for human enteroviruses in pigs, 39 and first evidence for influenza D virus in poultry. 40 We have found success through conducting monthly periodic surveillance in both live animal environments (industrialized farms, live animal markets, etc.) and among pneumonia patients in large hospitals for about $25,000 per year per site.

To conduct such effective surveillance, developed countries need to rethink current global security strategies and form better global health partnerships, embracing the interdisciplinary One Health approach to novel respiratory virus surveillance. Surveillance at the human-animal nexus is likely to be better focused and less expensive than some of the other strategies currently being contemplated.

Simultaneous outbreaks of respiratory disease in wild chimpanzees caused by distinct viruses of human origin

Human metapneumovirus infection in chimpanzees, United States. Emerg Infect Dis

Lethal Respiratory Disease Associated with Human Rhinovirus C in Wild Chimpanzees

Adenovirus Infections in African Humans and Wild Non-Human Primates: Great Diversity and Cross-Species Transmission. Viruses

Human metapneumovirus in turkey poults. Emerging Infectious Diseases

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis

A newly discovered human pneumovirus isolated from young children with respiratory tract disease

Do nonhuman primate or bat adenoviruses pose a risk for human health?

Are adenoviruses zoonotic? A systematic review of the evidence

A systematic review of evidence that enteroviruses may be zoonotic. Emerg Microbes Infect

The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region

Revised US surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases--United States and worldwide

Emerging viral respiratory tract infections--environmental risk factors and transmission. The Lancet infectious diseases

Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States

World Health Organization. WHO | Middle East respiratory syndrome coronavirus (MERS-CoV)

Global emergence of enterovirus D68: a systematic review

Enterovirus D68-associated acute respiratory illness-new vaccine surveillance network

Commission on Strengthening America's Health Security CfSIS. Biological Threats to U.S. National Security: Testimony before the Senate Armed Services Subcommittee on Emerging Threats and Capabilities

securitytestimony-before-the-senate-armed-services-subcommittee-on-emerging-threatsand-capabilities

Reverse spillover of avian viral vaccine strains from domesticated poultry to wild birds. Vaccine

World Bank Group. One Health Operational Framework for Strengthening Human, Animal, and Environmental Public Health Systems at Their Interface

The World Bank

Economic Impact of the 2015 MERS Outbreak on the Republic of Korea's Tourism-Related Industries. Health Secur

Predicting hotspots for influenza virus reassortment. Emerging Infectious Diseases

Global trends in emerging infectious diseases

Global hotspots and correlates of emerging zoonotic diseases

Evolution, and Recent Outbreaks of Avian Influenza Virus in China

Avian influenza A(H7N9) virus and mixed live poultry-animal markets in Guangdong province: a perfect storm in the making? Emerg Microbes Infect

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

Pandemics: spend on surveillance, not prediction

Predicting virus emergence amid evolutionary noise

Is It Possible to Predict the Next Pandemic Science The Atlantic

Can Virus Hunters Stop the Next Pandemic Before It Happens?

Before the Next Pandemic, an Ambitious Push to Catalog Viruses in Wildlife

COVID-19: A Wake-up Call for More Fundamental Research in Immunology

Prototype pathogen approach for pandemic preparedness: world on fire

Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic

Prospective surveillance for influenza

A RT-PCR assay for the detection of coronaviruses from four genera

Panspecies molecular assays detect viral pathogens missed by real-time PCR/reverse-transcriptase PCR among pneumonia patients

A c c e p t e d M a n u s c r i p t 15